- Home
- BKU vs SNY Comparison
BKU vs SNY Comparison
Compare BKU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- SNY
- Stock Information
- Founded
- BKU 2009
- SNY 1994
- Country
- BKU United States
- SNY France
- Employees
- BKU N/A
- SNY N/A
- Industry
- BKU Savings Institutions
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- SNY Health Care
- Exchange
- BKU Nasdaq
- SNY Nasdaq
- Market Cap
- BKU 2.6B
- SNY 116.5B
- IPO Year
- BKU 2011
- SNY N/A
- Fundamental
- Price
- BKU $37.68
- SNY $48.55
- Analyst Decision
- BKU Hold
- SNY Buy
- Analyst Count
- BKU 11
- SNY 2
- Target Price
- BKU $40.55
- SNY $62.50
- AVG Volume (30 Days)
- BKU 820.6K
- SNY 2.2M
- Earning Date
- BKU 07-23-2025
- SNY 07-31-2025
- Dividend Yield
- BKU 3.33%
- SNY 3.29%
- EPS Growth
- BKU 38.76
- SNY 39.56
- EPS
- BKU 3.21
- SNY 5.45
- Revenue
- BKU $972,198,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- BKU $13.53
- SNY $3.39
- Revenue Next Year
- BKU $6.80
- SNY $7.05
- P/E Ratio
- BKU $11.60
- SNY $8.90
- Revenue Growth
- BKU 11.13
- SNY N/A
- 52 Week Low
- BKU $28.21
- SNY $45.80
- 52 Week High
- BKU $44.45
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- BKU 64.05
- SNY 45.89
- Support Level
- BKU $36.93
- SNY $48.39
- Resistance Level
- BKU $38.13
- SNY $49.43
- Average True Range (ATR)
- BKU 0.81
- SNY 0.56
- MACD
- BKU 0.15
- SNY 0.16
- Stochastic Oscillator
- BKU 82.38
- SNY 52.94
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.